---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-129524"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T08:14:28.056185+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Intellia Therapeutics provides Phase 3 updates for NTLA-2002 and nex-z studies

## Summary
- HAELO study enrollment on track; expect completion Q3 2025, BLA submission H2 2026, potential US launch 2027.
- MAGNITUDE-2 study of nex-z for ATTRv-PN progressing; BLA submission by 2028, potential US launch 2029.
- MAGNITUDE study for nex-z in ATTR-CM enrolled ~365 of 765 patients; enrollment completion expected early 2027.
- Over 200 patients dosed with nex-z in MAGNITUDE; adverse events similar to Phase 1; one asymptomatic grade 4 liver elevation resolving.

## SEC filing metadata
- accession: 0001193125-25-129524
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312525129524/0001193125-25-129524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312525129524/d40487d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-129524
- JSON: https://secwatch.observer/filing/0001193125-25-129524.json
- Plain text: https://secwatch.observer/filing/0001193125-25-129524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.